Malaysian-based digital service provider Naluri Hidup announced on Wednesday the closing of a $5 million Series A funding round.
Besides the cornerstone investor, Singapore’s Intergra Partners, other strategic investors who participated in the fund include: Duopharma Biotech Bhd, Pathology Asia (via Biomark), and venture capital firm M Venture Partners, who were part of the company’s preceding round, Naluri said in a statement.
Naluri also added new investors to its cap table – Sumitomo, Corporation Equity Asia, Palm Drive Capital from New York, and INP Capital from Vancouver, Canada. The company also gain support from the Hibiscus Fund, a venture capital fund managed by Malaysia’s RHL Ventures and Korea’s KB Investment that are part of the government’s Dana Penjana National Programme.
Click here to read the full article by Deal Street Asia.
About Naluri Hidup Sdn Bhd
Naluri is a human-driven, Artificial Intelligence-augmented digital chronic disease management program that delivers quantifiable health outcomes and helps healthcare payors save on avoidable healthcare costs that uniquely addresses physical and mental health risks together, through structures, multi-disciplinary behavioural health coaching in a way that is twice as effective as medication alone and much more accessible.
Naluri has developed a distinctive model that solves challenges of existing digital health solutions, that is commercially validated. Its digital solution offers comparable levels of clinical effectiveness as medication, and ten-times lower cost that in-person therapy.
Naluri’s model aims to completely reimagine the current healthcare landscape and define the next generation (Healthcare 3.0) model beyond tele-health consultation services for chronic disease management. It has pioneered coordinated multi-disciplinary health coaching instead of a single specialist health coach model (Livongo) and using analytics and business process innovation to do it in a most cost – efficient manner (affordable by emerging markets).
Application of deep technology to quantify patient behaviours and mindsets to develop decision support tools and 10X productivity and effectiveness of coaches, leads to proven real-world clinical outcomes worth USD950million when compared to administration of drugs for clinical purposes.